Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does ischemic preconditioning afford clinically relevant cardioprotection?

Peter Mikhail1, Subodh Verma, Paul W M Fedak

  • 1Department of Surgery, Division of General Surgery, University of Toronto, Toronto, Canada.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|January 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A 3D-printed extravascular stent containing sirtuin-3 engineered human bone marrow mesenchymal stem cells maintains venous graft patency.

Stem cell research & therapy·2026
Same author

Pericardial Fluid-Derived Small Extracellular Vesicles from Patients with Coronary Disease Alter the Lipidome of Human Coronary Artery Endothelium.

CJC open·2026
Same author

CASPR2 antibody-related neurological syndromes in children: three cases report and literature review.

BMC pediatrics·2026
Same author

B cells drive CD4 T cell immunosenescence and age-associated health decline.

Science immunology·2026
Same author

Myocardial Infarction Elicits a Robust Inflammatory Response in the Pericardial Space.

The Canadian journal of cardiology·2025
Same author

Pericardial Delivery of Stem Cells: An Emerging Frontier in Myocardial Regeneration for Ischemic Heart Disease.

The Canadian journal of cardiology·2025
Same journal

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Clinical Pharmacology of Plozasiran.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Correction: Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Comment on "Polypill Strategy: A Paradigm Shift in Cardiovascular Disease Prevention".

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same journal

Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD?

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
See all related articles

Ischemic preconditioning protects heart cells from damage. While many studies show clinical relevance using surrogate markers, larger trials focusing on cell death are needed to confirm its benefits.

Area of Science:

  • Cardiology
  • Cellular Biology
  • Physiology

Background:

  • Ischemic preconditioning is a phenomenon where brief ischemia/reperfusion protects myocardial cells from prolonged ischemia.
  • Since 1986, significant research has explored this protective mechanism.

Purpose of the Study:

  • To review the molecular basis and clinical relevance of ischemic preconditioning.
  • To assess the existing clinical evidence and identify gaps in research.

Main Methods:

  • Literature review of studies on ischemic preconditioning.
  • Analysis of molecular mechanisms involving adenosine, bradykinin, opioids, and potassium channels.
  • Evaluation of clinical trial endpoints, including surrogate markers and cell death.

Related Experiment Videos

Main Results:

  • Over 33 clinical studies have investigated ischemic preconditioning, particularly in percutaneous transluminal coronary angioplasty and open-heart surgery.
  • Most studies utilize surrogate markers (cardiac enzymes, ejection fraction) rather than direct cell death.
  • Evidence supports clinical relevance, but definitive proof is lacking.

Conclusions:

  • Ischemic preconditioning demonstrates potential clinical benefits.
  • Further large-scale trials with morbidity and mortality as primary endpoints are essential.
  • Confirming clinical relevance requires direct assessment of cell death outcomes.